141 related articles for article (PubMed ID: 36853786)
21. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas.
Smit VT; Boot AJ; Smits AM; Fleuren GJ; Cornelisse CJ; Bos JL
Nucleic Acids Res; 1988 Aug; 16(16):7773-82. PubMed ID: 3047672
[TBL] [Abstract][Full Text] [Related]
22. Claudin-18 as a Marker for Identifying the Stomach and Pancreatobiliary Tract as the Primary Sites of Metastatic Adenocarcinoma.
Li WT; Jeng YM; Yang CY
Am J Surg Pathol; 2020 Dec; 44(12):1643-1648. PubMed ID: 32925194
[TBL] [Abstract][Full Text] [Related]
23. The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma.
Villaruz LC; Socinski MA; Cunningham DE; Chiosea SI; Burns TF; Siegfried JM; Dacic S
Cancer; 2013 Jun; 119(12):2268-74. PubMed ID: 23526491
[TBL] [Abstract][Full Text] [Related]
24. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
[TBL] [Abstract][Full Text] [Related]
25. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
Riely GJ; Kris MG; Rosenbaum D; Marks J; Li A; Chitale DA; Nafa K; Riedel ER; Hsu M; Pao W; Miller VA; Ladanyi M
Clin Cancer Res; 2008 Sep; 14(18):5731-4. PubMed ID: 18794081
[TBL] [Abstract][Full Text] [Related]
26. Targeted Sequencing of Pancreatic Adenocarcinomas from Patients with Metachronous Pulmonary Metastases.
Hlavac V; Mohelnikova-Duchonova B; Lovecek M; Ehrmann J; Brynychova V; Kolarova K; Soucek P
Genes (Basel); 2020 Nov; 11(12):. PubMed ID: 33255265
[TBL] [Abstract][Full Text] [Related]
27. LEF-1 is frequently expressed in colorectal carcinoma and not in other gastrointestinal tract adenocarcinomas: an immunohistochemical survey of 602 gastrointestinal tract neoplasms.
Kermanshahi TR; Jayachandran P; Chang DT; Pai R
Appl Immunohistochem Mol Morphol; 2014; 22(10):728-34. PubMed ID: 25394300
[TBL] [Abstract][Full Text] [Related]
28. Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases.
Marotti JD; Schwab MC; McNulty NJ; Rigas JR; DeLong PA; Memoli VA; Tsongalis GJ; Padmanabhan V
Diagn Cytopathol; 2013 Jan; 41(1):15-21. PubMed ID: 21681971
[TBL] [Abstract][Full Text] [Related]
29. Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas.
Schultz NA; Roslind A; Christensen IJ; Horn T; Høgdall E; Pedersen LN; Kruhøffer M; Burcharth F; Wøjdemann M; Johansen JS
Pancreas; 2012 Jul; 41(5):759-66. PubMed ID: 22699145
[TBL] [Abstract][Full Text] [Related]
30. Characteristic Mutational Damages in Gastric and Colorectal Adenocarcinomas.
Yermekova S; Orazgaliyeva M; Goncharova T; Rakhimbekova F; Kaidarova D; Shatkovskaya O
Asian Pac J Cancer Prev; 2023 Nov; 24(11):3939-3947. PubMed ID: 38019254
[TBL] [Abstract][Full Text] [Related]
31. GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas.
Ritterhouse LL; Vivero M; Mino-Kenudson M; Sholl LM; Iafrate AJ; Nardi V; Dong F
Mod Pathol; 2017 Dec; 30(12):1720-1727. PubMed ID: 28776576
[TBL] [Abstract][Full Text] [Related]
32. Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: a retrospective study of the Lebanese population.
Fakhruddin N; Mahfouz R; Farhat F; Tfayli A; Abdelkhalik R; Jabbour M; Yehia L; Mahfoud Z; Zaatari G
Oncol Rep; 2014 Nov; 32(5):2223-9. PubMed ID: 25120214
[TBL] [Abstract][Full Text] [Related]
33. Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy.
Cserepes M; Ostoros G; Lohinai Z; Raso E; Barbai T; Timar J; Rozsas A; Moldvay J; Kovalszky I; Fabian K; Gyulai M; Ghanim B; Laszlo V; Klikovits T; Hoda MA; Grusch M; Berger W; Klepetko W; Hegedus B; Dome B
Eur J Cancer; 2014 Jul; 50(10):1819-1828. PubMed ID: 24768329
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas.
Dacic S; Shuai Y; Yousem S; Ohori P; Nikiforova M
Mod Pathol; 2010 Feb; 23(2):159-68. PubMed ID: 19855375
[TBL] [Abstract][Full Text] [Related]
35. Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome.
Planck M; Isaksson S; Veerla S; Staaf J
Clin Cancer Res; 2013 Sep; 19(18):5116-26. PubMed ID: 23938291
[TBL] [Abstract][Full Text] [Related]
36. Frequent GNAS and KRAS mutations in pyloric gland adenoma of the stomach and duodenum.
Matsubara A; Sekine S; Kushima R; Ogawa R; Taniguchi H; Tsuda H; Kanai Y
J Pathol; 2013 Mar; 229(4):579-87. PubMed ID: 23208952
[TBL] [Abstract][Full Text] [Related]
37. Comparison of EGFR and KRAS mutations in primary and unpaired metastatic lung adenocarcinoma with potential chemotherapy effect.
Munfus-McCray D; Cui M; Zhang Z; Gabrielson E; Askin F; Li QK
Hum Pathol; 2013 Jul; 44(7):1286-92. PubMed ID: 23337026
[TBL] [Abstract][Full Text] [Related]
38. Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas.
Rehkaemper J; Korenkov M; Quaas A; Rueschoff J; Pamuk A; Zander T; Hillmer AM; Buettner R; Hoelscher AH; Bruns CJ; Loeser H; Alakus H; Schoemig-Markiefka B
BMC Cancer; 2020 Jun; 20(1):587. PubMed ID: 32571252
[TBL] [Abstract][Full Text] [Related]
39. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma.
Jun SY; Kim M; Jin Gu M; Kyung Bae Y; Chang HK; Sun Jung E; Jang KT; Kim J; Yu E; Woon Eom D; Hong SM
Mod Pathol; 2016 Apr; 29(4):402-15. PubMed ID: 26892442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
